

1 **The Contribution of Commonly Diagnosed Genetic Disorders to Small for Gestational**
2 **Age Birth and Subsequent Morbidity and Mortality in Preterm Infants**

3
4 Miles Bombback, MPH,¹ Selin Everett, BS,² Alex Lyford, PhD,³ Rakesh Sahni, MD,⁴ Faith Kim,
5 MD,⁴ Caitlin Baptiste, MD,² Joshua E. Motelow, MD, PhD,⁵ Veeral Tolia, MD,^{6,7,8} Reese Clark,
6 MD,⁶ Thomas Hays, MD, PhD⁴

7
8 ¹ Feinberg School of Medicine, Northwestern University, Chicago

9 ² Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Columbia
10 University Medical Center, New York City

11 ³ Middlebury College, Department of Mathematics, Middlebury, Vermont

12 ⁴ Division of Neonatology, Department of Pediatrics, Columbia University Irving Medical Center,
13 New York City

14 ⁵ Division of Critical Care and Hospital Medicine, Department of Pediatrics, Columbia University
15 Medical Center, New York City

16 ⁶ The Pediatrix Center for Research, Education, Quality and Safety, Sunrise, Florida

17 ⁷ Division of Neonatology, Department of Pediatrics, Baylor University Medical Center, Dallas,
18 Texas

19 ⁸ Pediatrix Medical Group, Dallas, Texas

20
21
22 Corresponding Author: Thomas Hays, th2712@cumc.columbia.edu, 622 West 168th S, Suite PH
23 17W-303, New York, New York, 10032

24
25 Word Count:

26

27 **Abstract**

28 **Objective:**

29 Preterm infants born small, vs. appropriate for gestational age (SGA, AGA) are at greater risk
30 for morbidity and mortality. The contribution of genetic disorders to preterm SGA birth,
31 morbidity, and mortality is unknown. We sought to determine the association between genetic
32 disorders and preterm SGA birth, and the association between genetic disorders and morbidity
33 or mortality within preterm SGA infants. We hypothesized that genetic disorders were
34 significantly associated with both.

35 **Study Design:**

36 This was a retrospective multicenter cohort study of 409 339 infants, born 23–33 weeks'
37 gestation between 2000 and 2020. The odds of preterm SGA (vs AGA) birth, and the odds of
38 severe morbidity or mortality within SGA preterm infants were determined for infants with
39 genetic disorders, after adjusting for known risk factors.

40 **Results:**

41 Genetic disorders were present in 3.0 and 1.3% of SGA and AGA preterm infants respectively;
42 genetic disorders conferred an aOR (95% CI) of 2.06 (1.92, 2.21) of SGA birth. Genetic
43 disorders were present in 4.3 of preterm SGA infants with morbidity or mortality and 2.1% of
44 preterm SGA infants that did not experience morbidity or mortality. Genetic disorders conferred
45 an aOR (95% CI) of 2.12 (2.66, 3.08) of morbidity or mortality.

46 **Conclusions:**

47 Genetic disorders are strongly associated with preterm SGA birth, morbidity, and mortality.
48 Clinicians should consider genetic testing of preterm SGA infants, particularly in the setting of
49 other comorbidities or anomalies. Prospective, genomic research is needed to clarify the
50 contribution of genetic disorders to disease in this population.

51

52

53

54 **Introduction**

55 Preterm infants experience a profound burden of morbidity and mortality, and small for
56 gestational age (SGA) birth is one of the strongest clinical risk factors for poor outcomes.¹⁻⁹
57 SGA is defined as birth weight less than the 10th percentile or two standard deviations below
58 mean for gestational age and sex based on estimates of population distributions.¹⁰⁻¹³ The
59 mechanism(s) by which SGA birth confers clinical risk are largely unknown. Known factors
60 including impaired metabolic reserve explain only a fraction of these outcomes.¹⁴ Although there
61 are known risks for SGA birth, including maternal, placental, infectious, genetic, and
62 environmental factors, the etiology of SGA birth is poorly understood. Known risks include
63 maternal.¹⁴⁻¹⁶

64

65 The overall contribution of genetic disorders to preterm SGA birth is unknown. Fetal growth
66 restriction (FGR) and continued poor fetal growth often impacts the decision to prematurely
67 deliver a fetus. Multiple studies have found genetic disorders associated with FGR.^{17,18} Higher
68 rates of aneuploidy and copy number variants are found in FGR, particularly when presenting
69 before 32 weeks' gestation or accompanied by other fetal anomalies.^{19,20} Metanalysis of exome
70 and genome sequencing for FGR demonstrated single gene disorders in 4% of isolated FGR
71 and 30% of FGR accompanied by other anomalies.¹⁷ Genetic disorders have been shown to
72 contribute to morbidity and severe mortality in related populations as well. Genetic disorders
73 have been found in 6% of stillbirths, 10% of fetal structural anomalies, and in 20% of cohorts of
74 pediatric critical illness or perinatal disease.²¹⁻²⁶

75

76 Given the burden of illness experienced by preterm SGA infants, emerging evidence that
77 genetic disorders cause FGR and SGA, and evidence that genetic disorders cause critical
78 illness in related populations, we sought to determine the contribution of commonly diagnosed

79 genetic disorders to preterm SGA birth, morbidity, and mortality. The Pediatrix Clinical
80 Datawarehouse (CDW) contains detailed health records of these infants, including the presence
81 of genetic disorders diagnosed during standard clinical care.

82

83 **Materials/Subjects and Methods:**

84 This study was approved by the institutional review board of Columbia University with a waiver
85 for informed consent. This was a retrospective multicenter cohort study using the Pediatrix
86 CDW. The CDW includes records from approximately 400 community and academic NICUs
87 (levels I–IV) in 35 US states and Puerto Rico, which provided care to approximately 20% of
88 preterm infants born in the United States during the study period. Data was entered by clinicians
89 using admission, progress, and discharge notes, as well as results from laboratory, imaging,
90 and other diagnostic studies. These data were then extracted, consolidated, and processed to
91 populate the CDW.²⁷ Data included demographic and maternal characteristics, diagnoses made
92 by clinicians (genetic disorders, morbidities), and hospital disposition (mortality, discharge
93 home, or transfer). The results of negative test results, including for genetic disorders, were not
94 available. Records of 409 399 infants born from 23 to 33 weeks' gestation, discharged from
95 2000 to 2020 were extracted. Data from NICU admission to discharge were collected. Birth
96 weight was normalized within the cohort by gestational age and sex. Cases were excluded if
97 these data were missing. Infants were classified as SGA for normalized birth weight below the
98 10th percentile or as appropriate for gestational age (AGA) at the 10th percentile or above and
99 less than the 90th percentile. Infants with birth weight greater than the 90th percentile were
100 excluded to prevent the confounding impact of poor outcomes in LGA infants. We determined
101 the overlap of this definition with SGA defined by Fenton criteria and by the Eunice Kennedy
102 Shriver National Institute of Child Health and Human Development (NICHD) consensus FGR
103 definition.^{10,28}

104

105 *Association of Genetic Disorders with SGA versus AGA birth among preterm infants*

106 We performed multiple variable logistic regression of the association of the following maternal
107 and infant characteristics: ethnicity/race (maternal self-declared), maternal age, diagnosis of
108 genetic disorders, the presence of congenital anomalies (defined as clinician diagnosed
109 anomalies of the heart, gastrointestinal tract, brain, lungs, kidneys and urinary tract, or the
110 presence of hydrops), and year of discharge. Congenital anomalies themselves are strongly
111 associated with genetic disorders. Therefore, we tested for an interaction between congenital
112 anomalies and genetic disorders with the outcome of SGA birth.

113

114 This analysis was also repeated limiting the cohort to infants born following singleton gestation
115 to test the effect of multiple gestation. Unadjusted odds of SGA versus AGA birth were
116 determined for each genetic disorder in which SGA birth was observed. The prevalence rate of
117 SGA birth across maternal age was also determined.

118

119 *Association of genetic disorders with morbidity and mortality within preterm SGA infants*

120 Next, we evaluated factors associated with severe morbidity or mortality within preterm SGA
121 infants. To limit ascertainment bias, infants transferred after birth or prior to discharge were
122 excluded from the analysis of clinical outcomes.²⁹ Multivariable logistic regression was
123 performed for severe morbidity or mortality as a combined clinical outcome. Severe morbidity
124 was defined as any of the following: acute kidney injury (AKI) defined by the diagnosis of
125 oliguria or anuria (ICD-9 788.5 or ICD-10: R34); severe intracranial hemorrhage (ICH) defined
126 as grade III or IV intraventricular hemorrhage by Papile criteria or cystic periventricular
127 leukomalacia;³⁰ medically or surgically treated necrotizing enterocolitis (NEC); severe
128 bronchopulmonary dysplasia (BPD) defined as invasive mechanical ventilation at 36 weeks'
129 postmenstrual age; severe retinopathy of prematurity (ROP) defined as need for any medical or
130 surgical intervention; culture-positive sepsis defined by any positive blood or urine culture; or

131 shock defined as administration of any vasopressor or inotrope. The following were covariates:
132 exposure to antenatal betamethasone, mode of delivery (vaginal delivery was treated as
133 reference), phenotypic sex (female was treated as reference given the associated risk of
134 morbidity in male infants),^{31,32} race (White race was treated as reference given the proportional
135 size), gestational age, birth weight Z-score, discharge year epoch (2000-2004, 2005-2009,
136 2010-2014, 2015-2020), intubation in the first 72 hours of life, presence of a known genetic
137 disorder, and the presence of congenital anomalies. This analysis was repeated limiting the
138 cohort to infants born following singleton gestation to test the effect of multiple gestations. As
139 before, we also tested for an interaction between genetic disorders and congenital anomalies
140 and the outcome of morbidity or mortality.

141

142 Finally, we sought to evaluate how SGA preterm infants with or without congenital anomalies
143 compared to AGA preterm infants with respect to rates of morbidity and mortality. Using AGA
144 preterm infants as reference for both analyses, we determined the crude odds ratios (OR) of
145 individual comorbidities for preterm infants born SGA without congenital anomalies and for
146 preterm infants born SGA with congenital anomalies. Analyses were made using RStudio
147 version 2022.07.0 (R Project for Statistical Computing) (eMethods in the **Supplement**).³³

148

149 **Results**

150 378 887 SGA and AGA infants were identified in this cohort (**Table 1**). Of these, 176 791
151 (46.7%) were female. The mean (SD) gestational age was 30.1 (2.86) weeks, and the mean
152 (SD) birth weight was 1.44 (0.49) kg. Genetic disorders were diagnosed in 5 386 (1.4%) infants.
153 Congenital anomalies were present in 24 463 (6.4%) of infants. 36 985 (9.8%) infants were
154 defined as SGA. 36 985 infants met this definition, all of whom were below the 10th percentile for
155 NICHD fetal growth (**Supplemental Figure 1**). 33 451 (92.1%) of these infants were also below
156 the Fenton 10th percentile definition of SGA birth.

157

158 *Association of Genetic Disorders with SGA versus AGA birth among preterm infants*

159 Genetic disorders were present in 1112 (3.0%) of the 36 985 preterm SGA infants and in 4274
160 (1.3%) of the 341 902 preterm AGA infants in this cohort. Multivariable logistic regression
161 demonstrated higher adjusted OR of SGA versus AGA birth for infants born to mothers
162 identifying as Asian or Black (versus White) and lower for those born to mothers identifying as
163 Hispanic (versus White) (**Figure 1**). Known genetic disorders and congenital anomalies (except
164 for fetal hydrops and pulmonary anomalies) were also found to be associated with SGA birth in
165 preterm infants. SGA birth was not found to vary across the period of this study (2000–2020).
166 Nearly identical results were found for all covariates when this regression was limited to infants
167 born following singleton gestation (**Supplemental Figure 2**). Greater maternal age was also
168 associated with SGA birth (**Figure 3**). The association between genetic disorders and SGA birth
169 was not driven by a single genetic disorder. Rather, SGA birth was associated with multiple
170 known diagnoses including trisomy 13, trisomy 18, trisomy 21, Turner syndrome, unspecified
171 aneuploidy, unspecified copy number variant, sickle cell anemia, cystic fibrosis,
172 hypophosphatasia, and the presence of multiple genetic disorders (**Supplemental Table 1**). As
173 a secondary analysis, we repeated this regression testing for an interaction between the
174 presence of genetic disorders and the presence of any congenital anomaly. We found that these
175 factors each independently associated with SGA versus AGA birth in preterm infants, but we did
176 not find a significant interaction between these factors and SGA birth.

177

178 *Association of genetic disorders with morbidity and mortality within preterm SGA infants*

179 We next focused on morbidity and mortality within the subset of 36 985 SGA preterm infants.
180 After excluding infants transferred in or to other facilities, and those with missing data, 28 983
181 SGA preterm infants remained (**Figure 2**). Genetic disorders were present in 375 (4.3%) of the
182 8810 preterm SGA infants that experienced severe morbidity or mortality as compared to 415

183 (2.1%) of the 20 173 preterm AGA infants that did not experience these outcomes. Antenatal
184 betamethasone, birth in later years, maternal identification as Asian or Black (versus White),
185 increased gestational age, and increased birth weight all were associated with lower adjusted
186 odds of morbidity or mortality. Male sex, maternal identification as Hispanic (versus White),
187 intubation in the first 72 hours of life, the presence of known genetic disorders, or congenital
188 anomalies were associated with greater adjusted odds of morbidity or mortality. Nearly identical
189 results were found for all covariates when this regression was limited to infants born following
190 singleton gestation pregnancy (**Supplemental Figure 3**). Compared to AGA preterm infants,
191 SGA preterm infants with or without other congenital anomalies experienced higher rates of
192 death and every comorbidity, with the exception of severe ICH, which was observed to occur
193 less frequently in infants with isolated SGA status compared to all AGA infants. (**Table 2**). As a
194 secondary analysis, we repeated this regression with a test for an interaction between the
195 presence of genetic disorders and the presence of any congenital anomaly. We found that SGA
196 preterm infants with genetic disorders and congenital anomalies had an adjusted odds ratio
197 (95% confidence interval) of 1.52 (1.03, 2.27) for severe morbidity or mortality.

198

199 **Discussion**

200 The primary finding of our study was that genetic disorders were strongly and nonspecifically
201 associated with preterm SGA birth, morbidity, and mortality. There are important strengths,
202 limitations, and clinical implications of this finding. Our analysis revealed several secondary
203 findings as well: lower birth weight and higher risk of illness in preterm infants with cystic fibrosis
204 and hypophosphatasia, a synergistic risk of illness in infants with congenital anomalies and
205 genetic disorders, and a lower rate of severe ICH in preterm SGA infants without congenital
206 anomalies. In the following we discuss the primary and secondary findings of our research.

207

208 Using a highly generalizable cohort, we found that commonly diagnosed genetic disorders were
209 twice as prevalent in SGA infants compared to AGA infants, and that genetic disorders were
210 strongly associated with SGA birth weight after adjusting for known risk factors. Genetic
211 disorders were also strongly associated with severe morbidity and mortality in this population.
212 We confirmed previously described associations between common aneuploidies and SGA birth,
213 morbidity, and mortality. Interestingly, we found a broad association between genetic disorders
214 and preterm SGA birth. Of the 20 genetic disorders analyzed (including “unspecified” cases of
215 aneuploidy or copy number variants), significant associations with SGA birth were found in 10,
216 and nonsignificant trends towards this association were found in 8. Cystic fibrosis has recently
217 been implicated as a cause of lower birth weight and earlier gestation of birth,³⁴ which our data
218 support. We also found evidence of a novel association between hypophosphatasia and
219 preterm SGA birth, as well as significantly greater odds of morbidity or mortality. If confirmed,
220 these findings might illuminate pathogenic mechanisms of growth restriction.

221
222 Multiple gestations have typically been excluded in large cohort studies limiting the
223 generalizability of findings. We found similar results with or without this exclusion. However, we
224 did not evaluate pairwise outcomes within twin or greater multiple gestations. Clinicians and
225 families, particularly in the setting of growth discordant twins, often must consider risks and
226 benefits in timing of delivery. Targeted focus on SGA multiple gestations could help better
227 inform these decisions, as well as validate twin-specific growth charts.³⁵ Unique factors in twin
228 pregnancies including unequal placentation, twin-twin transfusion, and birth weight discordance
229 all may influence clinical outcomes, and should be explored further.^{36,37}

230
231 In addition to genetic disorders, we found that congenital anomalies were strongly associated
232 with preterm SGA birth, morbidity, and mortality. Congenital anomalies of the kidney, heart,
233 brain, and other organ systems are themselves strongly linked to genetic disorders. It is unclear

234 if anomalies themselves caused lower birth weight and illness, or if anomalies were the sentinel
235 features of underlying genetic disorders. A parsimonious explanation is that underlying genetic
236 disorders contribute to congenital anomalies, poor fetal growth, and severe morbidity. This is
237 further supported by the finding that genetic disorders and congenital anomalies interacted to
238 confer synergistically greater risk of morbidity and mortality in SGA preterm infants.

239
240 Intriguingly, preterm SGA infants without congenital anomalies were found to have lower odds
241 of severe ICH compared to AGA infants. Fetal growth restriction and SGA birth have been
242 described as protective against severe intraventricular hemorrhage in extremely preterm (born <
243 28 weeks' gestation) infants.^{6,8,38-40} The implication of a lower risk of severe ICH in SGA birth
244 without other anomalies warrants attention given reports of higher risk of neurodevelopmental
245 impairment including poorer cognitive outcomes in this population.⁴¹ Administration of antenatal
246 corticosteroids reduces the risk of severe IVH and mortality, but studies have suggested that
247 steroids in SGA preterm infants may not reduce serious morbidities.^{42,43} Although a previous
248 landmark trial reported a potential reduction in severe IVH but no effect on neurosensory
249 impairment with the use of prophylactic indomethacin in extremely low birth weight infants,
250 multiple studies have refuted this finding.⁴⁴⁻⁴⁶ Replication, functional validation, and basic
251 investigation into protection of IVH in growth restricted extremely preterm infants may inform
252 novel therapies.

253
254 Our study had several compelling strengths. This represents the largest and most
255 comprehensive examination of factors associated with preterm SGA status and comorbidities to
256 our knowledge. This was a multicenter investigation of infants from diverse backgrounds, with
257 generalizable results. There are important limitations to this study. Infants born SGA may be
258 more likely to undergo pre- or postnatal genetic testing, especially in the presence of other
259 congenital anomalies or comorbidities. Details regarding testing, including time (pre- or

260 postnatal) and indication are unknown in this cohort. Genetic testing has also undergone
261 dramatic changes from 2000 to 2020. There is likely substantial heterogeneity in the genetic
262 workups performed across this period. Unfortunately, data are not available regarding the
263 spectrum of testing performed in the cohort, including negative results. There may also be
264 heterogeneity in the assignment of gestational age. The method used to determine this for each
265 individual in the cohort is unknown. Additionally, SGA and FGR are defined differently in the
266 literature of this field. We defined SGA birth here using the distribution of birth weight found
267 within this cohort. This definition increases the internal validity of our analysis but may limit
268 generalization. Given that our definition of SGA shared 92.1% with Fenton-defined SGA infants,
269 this is unlikely. The optimal criteria for defining a newborn as SGA or growth restricted likely
270 include individual environmental, genetic, and biological factors, many of which are yet
271 unknown. These analyses also did not consider when growth restriction occurred during
272 pregnancy, patterns of growth restriction (such as head-sparing or symmetric), fetal exposures,
273 postnatal growth patterns, or social determinants of health. Our dataset lacks maternal records,
274 including the presence of comorbidities that may contribute to placental insufficiency. Our
275 finding that extremes of maternal age, as well as increasing maternal age from 18 to 34 years,
276 were associated with SGA status likely reflects the contribution of these maternal factors.

277
278 Genetic counseling and consideration of testing for FGR is recommended by the American
279 College of Obstetricians and Gynecologists as well as by the Society for Maternal and Fetal
280 Medicine.^{47,48} There is not yet consensus regarding the postnatal evaluation of SGA infants.^{49,50}
281 Scarce data exist regarding how often genetic workups or testing are actually performed pre- or
282 postnatally for these indications. Furthermore, perinatal genetic disorders often present
283 nonspecifically and are often diagnosed belatedly.^{51,52} The indications and potential benefit for
284 genetic testing in this population is unknown without prospective, genome-wide testing.

285

286 Our findings have implications for clinical practice and further research. Clinicians should
287 strongly consider genetic testing of preterm SGA infants, particularly in the setting of other
288 comorbidities or anomalies. Genetic disorders were found in 3.0% of preterm SGA infants
289 overall and 4.3% of preterm SGA infants with severe morbidity and mortality. These represent
290 underestimates as prospective testing was not preformed. Without prospective genetic testing
291 the baseline rate genetic disorders in this population is unknown. Preterm SGA infants with
292 genetic disorders or congenital anomalies may be at higher risk for morbidity and mortality.
293 Clinicians should consider this risk when counseling families, evaluating the risks and benefits
294 of management decisions, or estimating the pre-test probability of diagnostic tests. Prospective
295 genomic research is urgently needed to clarify the contribution of genetic disorders to disease in
296 this population.

297

298

299

300 **Acknowledgements**

301 The authors wish to gratefully acknowledge Dr. Ali G. Gharavi (Columbia University Irving
302 Medical Center) and his research team, as well as Dr. Joseph M. Feinglass (Feinberg School of
303 Medicine, Northwestern University) for their mentorship and thoughtful review of this project.

304

305 Authors TH and JEM are supported by *Thrasher Research Fund Early Career Awards*. TH is
306 also supported by the *NIH National Center for Advancing Translational Sciences*
307 (KL2TR001874).

308

309

310 **Supplemental Materials**

311 **Supplemental Table 1.** Unadjusted odds of SGA birth within diagnosed genetic disorders.

312 **Supplemental Figure 1.** Classification of SGA or FGR birth in this cohort by related criteria.

313 **Supplemental Figure 2.** Multivariable logistic regression for SGA versus AGA status in preterm
314 infants with singleton gestation.

315 **Supplemental Figure 3.** Multivariable logistic regression for severe morbidity or mortality in
316 SGA preterm infants following singleton gestation.

317 **eMethods.** R studio script used for this project.

318 **Table 1.** Descriptive characteristics of cohort

Characteristic	AGA (N=341902)	SGA (N=36985)	P-value
Sex			
Female	159615 (46.7%)	17176 (46.4%)	0.375
Male	182287 (53.3%)	19809 (53.6%)	
Gestational Age (weeks)			
Mean (SD)	30.1 (2.88)	30.2 (2.69)	<0.001
Median [Min, Max]	31.0 [23.0, 33.0]	31.0 [23.0, 33.0]	
Race and Ethnicity			
Asian	9698 (2.8%)	1152 (3.1%)	<0.001
Black	79022 (23.1%)	10128 (27.4%)	
Hispanic	66839 (19.5%)	6157 (16.6%)	
Other	25385 (7.4%)	2851 (7.7%)	
White	160958 (47.1%)	16697 (45.1%)	
Maternal Age			
Mean (SD)	28.1 (6.52)	28.5 (6.57)	<0.001
Median [Min, Max]	28.0 [10.0, 60.0]	28.0 [10.0, 58.0]	
Missing	1494 (0.4%)	126 (0.3%)	
Discharge Year			
2000 to 2004	56242 (16.4%)	5979 (16.2%)	0.025
2005 to 2009	90974 (26.6%)	9809 (26.5%)	
2010 to 2014	91931 (26.9%)	9810 (26.5%)	
2015 to 2020	102755 (30.1%)	11387 (30.8%)	
Genetic Disorder			
Absent	337628 (98.8%)	35873 (97.0%)	<0.001
Present	4274 (1.3%)	1112 (3.0%)	
Congenital Anomaly			
Absent	321063 (93.9%)	33361 (90.2%)	<0.001
Kidney or urinary tract	5082 (1.5%)	834 (2.3%)	
Heart	5555 (1.6%)	925 (2.5%)	
Central nervous system	3718 (1.1%)	611 (1.7%)	
Gastrointestinal tract	3674 (1.1%)	649 (1.8%)	
Hydrops	321 (0.1%)	36 (0.1%)	
Multiple organ systems	2066 (0.6%)	513 (1.4%)	
Pulmonary	423 (0.1%)	56 (0.2%)	

319 Abbreviations: AGA (appropriate for gestational age), SGA (small for gestational age)

320 **Table 2.** Unadjusted odds of mortality or severe morbidities in preterm SGA infants.

Outcome	OR (99.44% CI)	
	Preterm SGA Infants without Congenital Anomalies (versus AGA Preterm Infants)	Preterm SGA Infants with Additional Congenital Anomalies (versus AGA Preterm Infants)
Mortality or any morbidity	1.45 (1.39, 1.50)	4.86 (4.33, 5.46)
Mortality	1.99 (1.87, 2.12)	5.96 (5.20, 6.83)
Acute kidney injury	1.60 (1.46, 1.75)	5.03 (4.22, 6.00)
Severe intracranial hemorrhage	0.82 (0.75, 0.91)	1.89 (1.52, 2.36)
Severe necrotizing enterocolitis	1.28 (1.18, 1.40)	3.50 (2.91, 4.21)
Severe bronchopulmonary dysplasia	2.40 (2.13, 2.70)	9.50 (7.78, 11.59)
Severe retinopathy of prematurity	1.52 (1.33, 1.74)	3.14 (2.31, 4.27)
Sepsis	1.37 (1.29, 1.45)	3.22 (2.81, 3.68)
Shock	1.35 (1.28, 1.43)	3.18 (2.78, 3.64)

321 Abbreviations: CI (confidence interval), OR (odds ratio), SGA (small for gestational age)

322

323

324


Variable	N	Odds ratio	p
Race and Ethnicity	White	177138	Reference
	Asian	10811	1.10 (1.04, 1.18) 0.002
	Black	88877	1.24 (1.21, 1.28) <0.001
	Hispanic	72747	0.89 (0.86, 0.92) <0.001
	Other	27694	1.07 (1.03, 1.12) 0.001
Maternal Age (years)	10-19	36857	Reference
	20-29	182044	1.12 (1.08, 1.16) <0.001
	30-39	142563	1.19 (1.15, 1.24) <0.001
	40-49	15600	1.33 (1.25, 1.42) <0.001
	50-60	203	1.54 (0.98, 2.29) 0.046
Discharge Year	2000 to 2004	62190	Reference
	2005 to 2009	100052	1.01 (0.97, 1.04) 0.717
	2010 to 2014	101153	0.98 (0.95, 1.02) 0.329
	2015 to 2020	113872	1.00 (0.97, 1.04) 0.939
Genetic Disorder	Absent	371906	Reference
	Present	5361	2.06 (1.92, 2.21) <0.001
Congenital Anomaly	Absent	352898	Reference
	Cardiac	6458	1.51 (1.41, 1.62) <0.001
	Gastrointestinal	4304	1.68 (1.55, 1.83) <0.001
	Hydrops	356	1.03 (0.72, 1.43) 0.869
	Multiple	2568	2.18 (1.97, 2.40) <0.001
	Neurological	4311	1.54 (1.41, 1.68) <0.001
	Pulmonary	476	1.28 (0.96, 1.68) 0.081
Renal	5896	1.58 (1.47, 1.70) <0.001	

325
 326 **Figure 1:** Multivariable regression of clinical characteristics of preterm infants born SGA versus
 327 AGA. Regression was performed for the outcome of SGA birth within infants born before 34
 328 weeks' gestation. Maternal identification as Hispanic was associated with lower adjusted odds
 329 of SGA status. Maternal identification as Asian or Black, advancing maternal age, the presence
 330 of a known genetic disorder, and the presence of congenital anomalies (excluding hydrops and
 331 pulmonary anomalies) were associated with greater adjusted odds of SGA status.

332
 333

Variable		N	Odds ratio	p
Antenatal Betamethasone	No	4688	Reference	
	Yes	24295	0.70 (0.64, 0.77)	<0.001
Sex	Female	13584	Reference	
	Male	15399	1.17 (1.10, 1.25)	<0.001
Race and Ethnicity	White	13117	Reference	
	Asian	929	0.80 (0.65, 0.98)	0.034
	Black	7955	0.88 (0.81, 0.95)	0.001
	Hispanic	4792	1.31 (1.19, 1.44)	<0.001
	Other	2190	0.93 (0.82, 1.07)	0.320
Gestational Age (weeks)		28983	0.61 (0.60, 0.62)	<0.001
Birth Weight (Z-score)		28983	0.40 (0.37, 0.43)	<0.001
Delivery Mode	Vaginal	2565	Reference	
	Cesarean Section	26418	0.64 (0.57, 0.73)	<0.001
Discharge Year	2000 to 2004	4423	Reference	
	2005 to 2009	7773	0.98 (0.89, 1.09)	0.734
	2010 to 2014	7883	0.70 (0.63, 0.78)	<0.001
	2015 to 2020	8904	0.62 (0.56, 0.69)	<0.001
Intubation within 72 Hours	No	17689	Reference	
	Yes	11294	2.86 (2.66, 3.08)	<0.001
Genetic Disorder	Absent	28193	Reference	
	Present	790	2.12 (1.77, 2.55)	<0.001
Congenital Anomaly	Absent	26645	Reference	
	Cardiac	568	2.07 (1.68, 2.56)	<0.001
	Gastrointestinal	373	5.11 (3.91, 6.71)	<0.001
	Hydrops	24	17.38 (4.93, 85.73)	<0.001
	Multiple	295	8.91 (6.65, 12.01)	<0.001
	Neurological	406	3.36 (2.62, 4.30)	<0.001
	Pulmonary	41	4.69 (2.23, 10.27)	<0.001
	Renal	631	2.29 (1.87, 2.81)	<0.001

334
 335 **Figure 2.** Multivariable logistic regression of clinical characteristics of preterm SGA infants with
 336 severe morbidity or mortality (versus preterm SGA infants without severe morbidity or mortality).
 337 Within the subset of preterm infants born SGA, regression was performed against the combined
 338 outcome of mortality or severe morbidity. Antenatal betamethasone, maternal identification as
 339 Asian or Black, increasing gestational age, increasing birth weight, cesarean delivery, and later
 340 epochs were found to be associated with lower adjusted odds of the composite outcome. Male
 341 sex, maternal identification as Hispanic, intubation after birth, and the presence of known
 342 genetic disorders or congenital anomalies were associated with greater adjusted odds of the
 343 composite outcome.
 344
 345



346
347 **Figure 3.** Prevalence of SGA birth by maternal age. The prevalence of SGA birth was
348 determined (within preterm births) for each year of maternal age from 15 to 50. Error bars depict
349 the 95% CI. Extreme maternal ages, less than 15 and greater than 50, were excluded from the
350 analysis due to their small sample size. For each one year increase in maternal age, on
351 average, there was a 0.107 increase in SGA prevalence per 100 preterm births (adjusted $r^2 =$
352 0.46, $p = <0.001$).

353
354
355
356
357

358 References

- 359 1. Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality
360 among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford
361 Network. *Am J Obstet Gynecol.* Jan 2000;182(1 Pt 1):198-206. doi:10.1016/s0002-
362 9378(00)70513-8
- 363 2. Zeitlin J, El Ayoubi M, Jarreau PH, et al. Impact of fetal growth restriction on mortality
364 and morbidity in a very preterm birth cohort. *J Pediatr.* Nov 2010;157(5):733-9.e1.
365 doi:10.1016/j.jpeds.2010.05.002
- 366 3. Peacock JL, Lo JW, D'Costa W, Calvert S, Marlow N, Greenough A. Respiratory
367 morbidity at follow-up of small-for-gestational-age infants born very prematurely. *Pediatr Res.*
368 Apr 2013;73(4 Pt 1):457-63. doi:10.1038/pr.2012.201
- 369 4. De Jesus LC, Pappas A, Shankaran S, et al. Outcomes of small for gestational age
370 infants born at <27 weeks' gestation. *J Pediatr.* Jul 2013;163(1):55-60.e1-3.
371 doi:10.1016/j.jpeds.2012.12.097
- 372 5. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and
373 mortality among premature neonates. *Am J Obstet Gynecol.* Aug 2004;191(2):481-7.
374 doi:10.1016/j.ajog.2004.01.036
- 375 6. Mendez-Figueroa H, Truong VT, Pedroza C, Chauhan SP. Morbidity and Mortality in
376 Small-for-Gestational-Age Infants: A Secondary Analysis of Nine MFMU Network Studies. *Am J*
377 *Perinatol.* Mar 2017;34(4):323-332. doi:10.1055/s-0036-1586502
- 378 7. Horbar JD, Carpenter JH, Badger GJ, et al. Mortality and neonatal morbidity among
379 infants 501 to 1500 grams from 2000 to 2009. *Pediatrics.* Jun 2012;129(6):1019-26.
380 doi:10.1542/peds.2011-3028
- 381 8. Baer RJ, Rogers EE, Partridge JC, et al. Population-based risks of mortality and preterm
382 morbidity by gestational age and birth weight. *J Perinatol.* Nov 2016;36(11):1008-1013.
383 doi:10.1038/jp.2016.118
- 384 9. Minor KC, Bianco K, Sie L, Druzin ML, Lee HC, Leonard SA. Severity of small-for-
385 gestational-age and morbidity and mortality among very preterm neonates. *J Perinatol.* Apr
386 2023;43(4):437-444. doi:10.1038/s41372-022-01544-w
- 387 10. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth
388 chart for preterm infants. *BMC Pediatr.* Apr 20 2013;13:59. doi:10.1186/1471-2431-13-59
- 389 11. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A.
390 Management of the child born small for gestational age through to adulthood: a consensus
391 statement of the International Societies of Pediatric Endocrinology and the Growth Hormone
392 Research Society. *J Clin Endocrinol Metab.* Mar 2007;92(3):804-10. doi:10.1210/jc.2006-2017
- 393 12. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P. International Small for
394 Gestational Age Advisory Board consensus development conference statement: management
395 of short children born small for gestational age, April 24-October 1, 2001. *Pediatrics.* Jun
396 2003;111(6 Pt 1):1253-61. doi:10.1542/peds.111.6.1253
- 397 13. Katz J, Lee AC, Kozuki N, et al. Mortality risk in preterm and small-for-gestational-age
398 infants in low-income and middle-income countries: a pooled country analysis. *Lancet.* Aug 3
399 2013;382(9890):417-425. doi:10.1016/s0140-6736(13)60993-9
- 400 14. Finken MJ, van der Steen M, Smeets CCJ, et al. Children Born Small for Gestational
401 Age: Differential Diagnosis, Molecular Genetic Evaluation, and Implications. *Endocr Rev.* Dec 1
402 2018;39(6):851-894. doi:10.1210/er.2018-00083
- 403 15. McCowan L, Horgan RP. Risk factors for small for gestational age infants. *Best Pract*
404 *Res Clin Obstet Gynaecol.* Dec 2009;23(6):779-93. doi:10.1016/j.bpobgyn.2009.06.003
- 405 16. Wollmann HA. Intrauterine growth restriction: definition and etiology. *Horm Res.* 1998;49
406 Suppl 2:1-6. doi:10.1159/000053079

- 407 17. Mone F, Mellis R, Gabriel H, et al. Should we offer prenatal exome sequencing for
408 intrauterine growth restriction or short long bones? A systematic review and meta-analysis. *Am*
409 *J Obstet Gynecol*. Oct 7 2022;doi:10.1016/j.ajog.2022.09.045
- 410 18. Meler E, Sisterna S, Borrell A. Genetic syndromes associated with isolated fetal growth
411 restriction. *Prenat Diagn*. Mar 2020;40(4):432-446. doi:10.1002/pd.5635
- 412 19. Peng R, Yang J, Xie HN, Lin MF, Zheng J. Chromosomal and subchromosomal
413 anomalies associated to small for gestational age fetuses with no additional structural
414 anomalies. *Prenat Diagn*. Dec 2017;37(12):1219-1224. doi:10.1002/pd.5169
- 415 20. Borrell A, Grande M, Meler E, et al. Genomic Microarray in Fetuses with Early Growth
416 Restriction: A Multicenter Study. *Fetal Diagn Ther*. 2017;42(3):174-180. doi:10.1159/000452217
- 417 21. Motelow JE, Lippa NC, Hostyk J, et al. Risk Variants in the Exomes of Children With
418 Critical Illness. *JAMA Netw Open*. Oct 3 2022;5(10):e2239122.
419 doi:10.1001/jamanetworkopen.2022.39122
- 420 22. Stanley KE, Giordano J, Thorsten V, et al. Causal Genetic Variants in Stillbirth. *N Engl J*
421 *Med*. Sep 17 2020;383(12):1107-1116. doi:10.1056/NEJMoa1908753
- 422 23. Petrovski S, Aggarwal V, Giordano JL, et al. Whole-exome sequencing in the evaluation
423 of fetal structural anomalies: a prospective cohort study. *Lancet*. Feb 23 2019;393(10173):758-
424 767. doi:10.1016/S0140-6736(18)32042-7
- 425 24. Lord J, McMullan DJ, Eberhardt RY, et al. Prenatal exome sequencing analysis in fetal
426 structural anomalies detected by ultrasonography (PAGE): a cohort study. *Lancet*. Feb 23
427 2019;393(10173):747-757. doi:10.1016/S0140-6736(18)31940-8
- 428 25. Bertoli-Avella AM, Beetz C, Ameziane N, et al. Successful application of genome
429 sequencing in a diagnostic setting: 1007 index cases from a clinically heterogeneous cohort.
430 *Eur J Hum Genet*. Jan 2021;29(1):141-153. doi:10.1038/s41431-020-00713-9
- 431 26. Hays T, Wapner RJ. Genetic testing for unexplained perinatal disorders. *Curr Opin*
432 *Pediatr*. Apr 1 2021;33(2):195-202. doi:10.1097/MOP.0000000000000999
- 433 27. Spitzer AR, Ellsbury DL, Handler D, Clark RH. The Pediatrix BabySteps Data
434 Warehouse and the Pediatrix QualitySteps improvement project system--tools for "meaningful
435 use" in continuous quality improvement. *Clin Perinatol*. Mar 2010;37(1):49-70.
436 doi:10.1016/j.clp.2010.01.016
- 437 28. Grantz KL, Grewal J, Kim S, et al. Unified standard for fetal growth: the Eunice Kennedy
438 Shriver National Institute of Child Health and Human Development Fetal Growth Studies. *Am J*
439 *Obstet Gynecol*. Apr 2022;226(4):576-587.e2. doi:10.1016/j.ajog.2021.12.006
- 440 29. Tolia VN, Clark RH. The Denominator Matters! Lessons from Large Database Research
441 in Neonatology. *Children (Basel)*. Nov 7 2020;7(11):216-216. doi:10.3390/children7110216
- 442 30. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal
443 and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. *J*
444 *Pediatr*. Apr 1978;92(4):529-34. doi:10.1016/s0022-3476(78)80282-0
- 445 31. Stevenson DK, Verter J, Fanaroff AA, et al. Sex differences in outcomes of very low
446 birthweight infants: the newborn male disadvantage. *Arch Dis Child Fetal Neonatal Ed*. Nov
447 2000;83(3):F182-5. doi:10.1136/fn.83.3.f182
- 448 32. Peacock JL, Marston L, Marlow N, Calvert SA, Greenough A. Neonatal and infant
449 outcome in boys and girls born very prematurely. *Pediatr Res*. Mar 2012;71(3):305-10.
450 doi:10.1038/pr.2011.50
- 451 33. *R: A language and environment for statistical computing*. R Foundation for Statistical
452 Computing; 2022. <https://www.R-project.org/>
- 453 34. Schlüter DK, Griffiths R, Adam A, et al. Impact of cystic fibrosis on birthweight: a
454 population based study of children in Denmark and Wales. *Thorax*. 2019;74(5):447-454.
455 doi:10.1136/thoraxjnl-2018-211706

- 456 35. Giorgione V, Briffa C, Di Fabrizio C, Bhate R, Khalil A. Perinatal Outcomes of Small for
457 Gestational Age in Twin Pregnancies: Twin vs. Singleton Charts. *J Clin Med*. Feb 8
458 2021;10(4)doi:10.3390/jcm10040643
- 459 36. D'Antonio F, Khalil A, Dias T, Thilaganathan B. Weight discordance and perinatal
460 mortality in twins: analysis of the Southwest Thames Obstetric Research Collaborative (STORK)
461 multiple pregnancy cohort. *Ultrasound Obstet Gynecol*. Jun 2013;41(6):643-8.
462 doi:10.1002/uog.12412
- 463 37. Townsend R, Khalil A. Fetal growth restriction in twins. *Best Pract Res Clin Obstet*
464 *Gynaecol*. May 2018;49:79-88. doi:10.1016/j.bpobgyn.2018.02.004
- 465 38. Kim F, Bateman DA, Goldshtrom N, Sheen J-J, Garey D. Intracranial ultrasound
466 abnormalities and mortality in preterm infants with and without fetal growth restriction stratified
467 by fetal Doppler study results. *Journal of Perinatology*. 2023/01/30 2023;doi:10.1038/s41372-
468 023-01621-8
- 469 39. Procianoy RS, Garcia-Prats JA, Adams JM, Silvers A, Rudolph AJ. Hyaline membrane
470 disease and intraventricular haemorrhage in small for gestational age infants. *Arch Dis Child*.
471 Jul 1980;55(7):502-5. doi:10.1136/adc.55.7.502
- 472 40. Gilbert WM, Danielsen B. Pregnancy outcomes associated with intrauterine growth
473 restriction. *American Journal of Obstetrics and Gynecology*. 2003/06/01/ 2003;188(6):1596-
474 1601. doi:<https://doi.org/10.1067/mob.2003.384>
- 475 41. Sacchi C, Marino C, Nosarti C, Vieno A, Visentin S, Simonelli A. Association of
476 Intrauterine Growth Restriction and Small for Gestational Age Status With Childhood Cognitive
477 Outcomes: A Systematic Review and Meta-analysis. *JAMA Pediatr*. Aug 1 2020;174(8):772-
478 781. doi:10.1001/jamapediatrics.2020.1097
- 479 42. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating
480 fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*. Mar 21
481 2017;3(3):Cd004454. doi:10.1002/14651858.CD004454.pub3
- 482 43. Blankenship SA, Brown KE, Simon LE, Stout MJ, Tuuli MG. Antenatal corticosteroids in
483 preterm small-for-gestational age infants: a systematic review and meta-analysis. *Am J Obstet*
484 *Gynecol MFM*. Nov 2020;2(4):100215. doi:10.1016/j.ajogmf.2020.100215
- 485 44. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis
486 in extremely-low-birth-weight infants. *N Engl J Med*. Jun 28 2001;344(26):1966-72.
487 doi:10.1056/nejm200106283442602
- 488 45. Mirza H, Laptook AR, Oh W, et al. Effects of indomethacin prophylaxis timing on
489 intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants.
490 *Arch Dis Child Fetal Neonatal Ed*. Sep 2016;101(5):F418-22. doi:10.1136/archdischild-2015-
491 309112
- 492 46. Foglia EE, Roberts RS, Stoller JZ, Davis PG, Haslam R, Schmidt B. Effect of
493 Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk
494 of Severe Intraventricular Hemorrhage. *Neonatology*. 2018;113(2):183-186.
495 doi:10.1159/000485172
- 496 47. Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. *Obstet Gynecol*. Feb 1
497 2021;137(2):e16-e28. doi:10.1097/aog.0000000000004251
- 498 48. Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series
499 #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline
500 Number 3, April 2012). *Am J Obstet Gynecol*. Oct 2020;223(4):B2-b17.
501 doi:10.1016/j.ajog.2020.05.010
- 502 49. Dauber A. Genetic Testing for the Child With Short Stature-Has the Time Come To
503 Change Our Diagnostic Paradigm? *J Clin Endocrinol Metab*. Jul 1 2019;104(7):2766-2769.
504 doi:10.1210/jc.2019-00019
- 505 50. Rapaport R, Wit JM, Savage MO. Growth failure: 'idiopathic' only after a detailed
506 diagnostic evaluation. *Endocr Connect*. Mar 2021;10(3):R125-r138. doi:10.1530/ec-20-0585

- 507 51. Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and clinical utility of
508 genome and exome sequencing and chromosomal microarray in children with suspected
509 genetic diseases. *NPJ Genom Med*. 2018;3(1):16. doi:10.1038/s41525-018-0053-8
510 52. Wojcik MH, Schwartz TS, Yamin I, et al. Genetic disorders and mortality in infancy and
511 early childhood: delayed diagnoses and missed opportunities. *Genet Med*. Nov
512 2018;20(11):1396-1404. doi:10.1038/gim.2018.17
513
- 514


515 **Supplemental Table 1.** Unadjusted odds of SGA birth associated for specific genetic disorders.

Genetic Disorder	SGA (n)	AGA (n)	OR (99.75% CI)
Aneuploidy			
Trisomy 13	32	109	2.76 (1.50–5.08)
Trisomy 18	145	80	17.06 (11.19-26.00)
Trisomy 21	286	987	2.73 (2.22-3.34)
Trisomy 22	1	2	4.71 (0.12-190.89)
Turner syndrome	17	34	4.71 (1.92-11.55)
Klinefelter syndrome	9	35	2.42 (0.78-7.49)
Unspecified aneuploidy	204	554	3.47 (2.70-4.44)
Copy Number Variant			
13q deletion	3	8	3.53 (0.46-27.33)
Cri-du-chat	4	17	2.21 (0.41-11.88)
DiGeorge syndrome	9	54	1.57 (0.53-4.66)
Unspecified copy number variant	15	31	4.55 (1.76-11.79)
Hematologic Single Gene Disorder			
Hemophilia A	1	12	0.78 (0.03-18.25)
Thalassemia	169	1256	1.27 (0.99-1.62)
Hemoglobin Bart's	39	391	0.94 (0.56-1.56)
Sickle cell anemia	48	196	2.30 (1.42-3.75)
G6PD deficiency	32	200	1.51 (0.85-2.68)

Genetic Disorder	SGA (n)	AGA (n)	OR (99.75% CI)
Fanconi anemia	2	1	18.82 (0.46-763.54)
Miscellaneous			
Cystic fibrosis	48	206	2.19 (1.35-3.56)
Hypophosphatasia	41	80	4.82 (2.70-8.62)
Multiple diagnoses	7	9	7.32 (1.60-33.59)

516
517 Abbreviations: AGA (appropriate for gestational age), CI (confidence interval), OR (odds ratio),
518 SGA (small for gestational age)
519

520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541



Supplemental Figure 1. Classification of SGA or FGR birth in this cohort by related criteria.

This cohort included 409,399 preterm infants from the Pediatrix CDW. SGA was defined for this study as below the 10th percentile for gestational age and sex within the CDW cohort. 36,985 infants met this definition, all of whom were below the 10th percentile for NICHD fetal growth.

33,451 (92.1%) of these infants also fell below the Fenton 10th percentile definition of SGA birth.

The numbers of infants meeting these criteria are depicted in the Euler diagram above.

542

Variable	N	Odds ratio	p
Race and Ethnicity	White	111314	Reference
	Asian	7672	1.02 (0.94, 1.10) 0.7
	Black	67874	1.18 (1.14, 1.22) <0.001
	Hispanic	55644	0.82 (0.79, 0.85) <0.001
	Other	19812	1.03 (0.98, 1.08) 0.3
Maternal Age (years)	10-19	29599	Reference
	20-29	129969	1.17 (1.12, 1.22) <0.001
	30-39	92726	1.26 (1.21, 1.32) <0.001
	40-49	9971	1.39 (1.29, 1.50) <0.001
	50-60	51	1.16 (0.40, 2.65) 0.8
Discharge Year	2000 to 2004	36019	Reference
	2005 to 2009	71117	1.02 (0.97, 1.06) 0.5
	2010 to 2014	72055	1.01 (0.97, 1.05) 0.7
	2015 to 2020	83125	1.02 (0.98, 1.07) 0.3
Genetic Disorder	Absent	258130	Reference
	Present	4186	2.09 (1.93, 2.25) <0.001
Congenital Anomaly	Absent	243621	Reference
	Cardiac	4665	1.40 (1.28, 1.52) <0.001
	Gastrointestinal	3506	1.52 (1.38, 1.67) <0.001
	Hydrops	279	1.06 (0.71, 1.52) 0.8
	Multiple	2051	1.94 (1.73, 2.17) <0.001
	Neurological	3455	1.38 (1.25, 1.53) <0.001
	Pulmonary	360	1.29 (0.93, 1.75) 0.1
Renal	4379	1.56 (1.43, 1.69) <0.001	

543 **Supplemental Figure 2.** Multivariable logistic regression for SGA versus AGA status in preterm
 544 infants with singleton gestation. The outcome of preterm SGA status was modeled as before
 545 (**Figure 1**) in only infants born following singleton gestation. Nearly identical adjusted odds were
 546 found for all covariates.

547

548

549

Variable	N	Odds ratio	p
Antenatal Betamethasone	No	3537	Reference
	Yes	17542	0.66 (0.60, 0.73) <0.001
Sex	Female	9753	Reference
	Male	11326	1.17 (1.08, 1.26) <0.001
Race and Ethnicity	White	8780	Reference
	Asian	655	0.76 (0.59, 0.96) 0.03
	Black	6290	0.92 (0.84, 1.01) 0.09
	Hispanic	3712	1.44 (1.29, 1.60) <0.001
Other	1642	0.99 (0.85, 1.15) 0.86	
Gestational Age (weeks)	21079	0.61 (0.60, 0.62) <0.001	
Birth Weight (Z-score)	21079	0.38 (0.35, 0.42) <0.001	
Delivery Mode	Vaginal	1948	Reference
	Cesarean Section	19131	0.60 (0.52, 0.70) <0.001
Discharge Year	2000 to 2004	2651	Reference
	2005 to 2009	5683	1.01 (0.89, 1.14) 0.93
	2010 to 2014	5893	0.72 (0.64, 0.82) <0.001
	2015 to 2020	6852	0.66 (0.58, 0.75) <0.001
Intubation within 72 Hours	No	12387	Reference
	Yes	8692	2.85 (2.61, 3.10) <0.001
Genetic Disorder	Absent	20445	Reference
	Present	634	2.17 (1.77, 2.66) <0.001
Congenital Anomaly	Absent	19301	Reference
	Cardiac	411	2.10 (1.63, 2.69) <0.001
	Gastrointestinal	292	5.67 (4.17, 7.74) <0.001
	Hydrops	19	14.69 (3.93, 75.11) <0.001
	Multiple	222	8.91 (6.37, 12.57) <0.001
	Neurological	316	3.07 (2.32, 4.06) <0.001
	Pulmonary	30	7.61 (3.07, 20.95) <0.001
	Renal	488	1.98 (1.57, 2.50) <0.001

550

551 **Supplemental Figure 3.** Multivariable logistic regression for severe morbidity or mortality in
 552 SGA preterm infants following singleton gestation. The combined outcome of mortality or severe
 553 morbidity status for preterm SGA infants was modeled as before (**Figure 2**) in only infants born
 554 following singleton gestation. Nearly identical adjusted odds were found for all covariates.

555

556

557 eMethods

558

559 The following script was used to generate tables and figures. The script was created using RStudio

560 (version 2022.07.0).

561

562 ##### Table 1

563

564 ## Import Data

565

566 setwd("/Users/Miles/Desktop")

567 Prevalence <- read.csv("Prev_Update_GxDx.csv")

568 Prevalence1 <- Prevalence

569 library(dplyr)

570 library(table1)

571

572 ## Data cleaning

573

574 Prevalence2 <- Prevalence1 %>% filter(BW_Z_Score <= 1.282)

575

576 Prevalence3 <- Prevalence2 %>% mutate(SGA = case_when (BW_Z_Score < -1.282 ~ 'SGA',

577 BW_Z_Score >= -1.282 ~ 'AGA'))

578

579 Prevalence4 <- Prevalence3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present"))

580

581 Prevalence4\$DY <- as.factor(ifelse(Prevalence4\$DischargeYear < 2005, "2000 to 2004",

582 ifelse(Prevalence4\$DischargeYear < 2010, "2005 to 2009", ifelse(Prevalence4\$DischargeYear < 2015,

583 "2010 to 2014", "2015 to 2020"))))

584

585 ## Label Data

586

587 label(Prevalence4\$BW) <- "Birthweight (kg)"

588 label(Prevalence4\$GA) <- "Gestational Age (weeks)"

589 label(Prevalence4\$GxDx) <- "Known Genetic Disorder"

590 label(Prevalence4\$Any_Anom) <- "Congenital Anomaly"

591 label(Prevalence4\$SGA) <- "SGA Birth"

592 label(Prevalence4\$Genetic) <- "Genetic Disorder"

593

594 ## Calculate p-values for Table1

595

596 pvalue <- function(x, ...) {

597 # Construct vectors of data y, and groups (strata) g

598 y <- unlist(x)

599 g <- factor(rep(1:length(x), times=sapply(x, length)))

600 if (is.numeric(y)) {

601 # For numeric variables, perform a standard 2-sample t-test

602 p <- t.test(y ~ g)\$p.value

603 } else {

604 # For categorical variables, perform a chi-squared test of independence

605 p <- chisq.test(table(y, g))\$p.value

606 }

607 # Format the p-value, using an HTML entity for the less-than sign.

608 # The initial empty string places the output on the line below the variable label.

609 c("", sub("<", "<", format.pval(p, digits=3, eps = 1e-200)))

610 }

611

612 ## Table 1

```
613
614 table1(~ Sex + GA + Race + MaternalAge + DY + Genetic + Any_Anom |SGA, data=Prevalence4,
615 overall=F, extra.col=list(`P-value`=pvalue))
616

617 ####Table 2:
618
619 ##Inport Data
620
621 setwd("/Users/Miles/Desktop")
622 Outcome <- read.csv("Outcome_Update_GxDx.csv")
623 Outcome1 <- Outcome
624 library(dplyr)
625
626 ## Clean the data and make new varriables
627
628 Outcome2 <- Outcome1 %>% mutate(SGA = case_when (BW_Z_Score < -1.282 ~ '1', BW_Z_Score >= -
629 1.282 ~ '0'))
630
631 Outcome3 <- Outcome2 %>% filter(BW_Z_Score <= 1.282)
632
633 Outcome4 <- Outcome3 %>% mutate(Additional_Anom = ifelse(Any_Anom == "Absent", "0", "1"))
634
635 ##Perform sum calculations
636 sum(Outcome4$SGA == "1" & Outcome4$Additional_Anom == "1" & Outcome4$CritIllorDeath == "Y")
637 ##Used this model for all the possible scenarios and then put them into an excel sheet
638 ##Excel Table 2 and Figure_2 were created for export
639
640 ## Load packages
641
642 library(tidyverse)
643 library(pixiedust)
644 library(kableExtra)
645 library(webshot)
646
647 ##Load data
648
649 Pos <-read.csv("Figure_2_Bonferroni_Corrected.csv")
650
651 tbl1 <- dust(Pos)
652
653 ##Plot
654
655 tbl1 %>%
656   sprinkle_colnames(Outcome = "Outcome*", Isolated = "Isolated SGA", Syndromic= "SGA with Additional
657   Congenital Anomaly") %>%
658   kable() %>% kable_styling() %>%
659   add_header_above(c(" " = 1, "OR (95% CI)" = 2))%>%
660   kable_classic(full_width = F, html_font = "Arial") %>%
661   footnote("AKI: acute kidney injury, ICH: intracranial hemorrhage, NEC: necrotizing enterocolitis, BPD:
662   bronchopulmonary dysplasia, ROP: retinopathy of prematurity", general_title = "*Abbreviations")
663

664 ####Figure 1
665
666 ##import data
```

```
667
668 setwd("/Users/Miles/Desktop")
669 Prevalence <- read.csv("Prev_Update_GxDx.csv")
670 Prevalence1 <- Prevalence
671 library(dplyr)
672
673 ##clean data and make new variables
674
675 Prevalence2 <- Prevalence1 %>% filter(BW_Z_Score <= 1.282)
676 Prevalence3 <- Prevalence2 %>% mutate(SGA = case_when (BW_Z_Score < -1.282 ~ '1', BW_Z_Score
677 >= -1.282 ~ '0'))
678 Prevalence4 <- Prevalence3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present"))
679 Prevalence4$MA <- as.factor(ifelse(Prevalence4$MaternalAge < 20, "10-19",
680 ifelse(Prevalence4$MaternalAge < 30, "20-29", ifelse(Prevalence4$MaternalAge < 40, "30-39",
681 ifelse(Prevalence4$MaternalAge < 50, "40-49", "50-60")))))
682 Prevalence4$Any_Anom <- as.factor(ifelse(Prevalence4$Any_Anom == "AG", "Genital",
683 ifelse(Prevalence4$Any_Anom == "CAKUT", "Renal", ifelse(Prevalence4$Any_Anom == "CHD",
684 "Cardiac", ifelse(Prevalence4$Any_Anom == "CNS", "Neurological", ifelse(Prevalence4$Any_Anom ==
685 "GI", "Gastrointestinal", ifelse(Prevalence4$Any_Anom == "Pulm", "Pulmonary",
686 ifelse(Prevalence4$Any_Anom == "Hydrops", "Hydrops", ifelse(Prevalence4$Any_Anom == "Multiple",
687 "Multiple", "Absent"))))))))
688 Prevalence4$DY <- as.factor(ifelse(Prevalence4$DischargeYear < 2005, "2000 to 2004",
689 ifelse(Prevalence4$DischargeYear < 2010, "2005 to 2009", ifelse(Prevalence4$DischargeYear < 2015,
690 "2010 to 2014", "2015 to 2020"))))
691
692 ##load packages
693
694 library(Hmisc)
695 library(expss)
696 library(gtsummary)
697 library(forestmodel)
698 library(lme4)
699
700 ##label data
701
702 Prevalence4$DischargeYear <- factor(Prevalence4$DischargeYear)
703 Prevalence4$Race <- factor(Prevalence4$Race)
704
705 Prevalence4$Race <- relevel(Prevalence4$Race, ref = "White")
706 Prevalence4$SGA <- factor(Prevalence4$SGA)
707 Prevalence4$Race <- factor(Prevalence4$Race)
708 Prevalence4$Sex <- factor(Prevalence4$Sex)
709 Prevalence4$Any_Anom <- factor(Prevalence4$Any_Anom)
710 Prevalence4$MA <- factor(Prevalence4$MA)
711 Prevalence4$DY <- factor(Prevalence4$DY)
712
713 label(Prevalence4$MA) <- "Maternal Age (years)"
714 label(Prevalence4$Race) <- "Race and Ethnicity"
715 label(Prevalence4$Genetic) <- "Genetic Disorder"
716 label(Prevalence4$Any_Anom) <- "Congenital Anomaly"
717 label(Prevalence4$DY) <- "Discharge Year"
718
719 ##multiple variable logistic regression model
720 LogReg3 <- glm(SGA~ Race + MA + DY + Genetic + Any_Anom, data = Prevalence4, family =
721 "binomial")
722 ##table depiction of model
```

```
723 forest_model(LogReg3, factor_separate_line = FALSE)
724
725 #####Figure 2:
726
727 ##Load data
728
729 setwd("/Users/Miles/Desktop")
730 Outcome <- read.csv("Outcome_Update_GxDx.csv")
731 Outcome1 <- Outcome
732 library(dplyr)
733
734 ##data preparation
735
736 Outcome2 <- Outcome1 %>% filter(BW_Z_Score <= 1.282)
737 Outcome3 <- Outcome2 %>% mutate(SGA = case_when (BW_Z_Score < -1.282 ~ '1', BW_Z_Score >= -
738 1.282 ~ '0'))
739 Outcome4 <- Outcome3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present"))
740 Outcome5 <- Outcome4 %>% filter(SGA == "1")
741 Outcome5$DY <- as.factor(ifelse(Outcome5$DischargeYear < 2005, "2000 to 2004",
742 ifelse(Outcome5$DischargeYear < 2010, "2005 to 2009", ifelse(Outcome5$DischargeYear < 2015, "2010
743 to 2014", "2015 to 2020"))))
744 Outcome6 <- Outcome5 %>% mutate(AntSter = ifelse(Antenatal.Steroids == "0", "No", "Yes"))
745 Outcome7 <- Outcome6 %>% mutate(MV72 = ifelse(MVD0.2 == "N", "No", "Yes"))
746 Outcome8 <- Outcome7 %>% filter(Deliv_Mode == "Cesarean Section" | Deliv_Mode == "Vaginal
747 Delivery")
748
749 ##load required packages
750
751 library(expss)
752 library(gtsummary)
753 library(forestmodel)
754 library(lme4)
755 library(Hmisc)
756
757 ##Label data
758
759 Outcome8$Sex <- factor(Outcome8$Sex)
760 Outcome8$Race <- factor(Outcome8$Race)
761 Outcome8$AntSter <- factor(Outcome8$AntSter)
762 Outcome8$CritIllorDeath <- factor(Outcome8$CritIllorDeath)
763 Outcome8$MV72 <- factor(Outcome8$MV72)
764 Outcome8$DY <- factor(Outcome8$DY)
765
766 Outcome8$Sex <- relevel(Outcome8$Sex, ref = "Female")
767 Outcome8$Race <- relevel(Outcome8$Race, ref = "White")
768
769 label(Outcome8$AntSter) <- "Antenatal Steroids"
770 label(Outcome8$Race) <- "Race and Ethnicity"
771 label(Outcome8$Genetic) <- "Genetic Disorder"
772 label(Outcome8$Any_Anom) <- "Congenital Anomaly"
773 label(Outcome8$DY) <- "Discharge Year"
774 label(Outcome8$MV72) <- "MV within 72 Hours"
775 label(Outcome8$GA) <- "Gestational Age (weeks)"
776 label(Outcome8$BW_Z_Score) <- "Birth Weight (Z-score)"
777
```



```
778 ## multiple variable logistic regression model
779
780 LogReg <- glm(CritIllorDeath ~ AntSter + Sex + Race + GA + BW_Z_Score + Deliv_Mode + DY + MV72
781 + Genetic + Any_Anom, data = Outcome8, family = "binomial")
782
783 ##table depiction of model
784
785 forest_model(LogReg, factor_separate_line = FALSE)
786
787 ####Figure 3:
788
789 ##load data
790
791 setwd("/Users/Miles/Desktop")
792 Prevalence <- read.csv("MA_V_Prev_per_100_Garphing.csv")
793 Prevalence1 <- Prevalence
794
795 ##uplaod required packages
796
797 library(dplyr)
798 library("ggplot2")
799
800
801 ##define and make plot
802
803 df <- ggplot(Prevalence1, aes(MA, Prev_Per_100)) + geom_point() + geom_errorbar(aes(ymin =
804 Low_per_100, ymax = Upp_per_100))
805
806 df + geom_point() + scale_x_continuous(breaks=seq(0, 60, 5)) + labs (x = 'Maternal Age (Years)', y =
807 'SGA Prevalence per 100 Preterm Births') + theme_bw() + theme(panel.border = element_blank(),
808 panel.grid.major = element_blank(),
809 panel.grid.minor =
810 element_blank(), axis.line = element_line(colour = "black"))
811
812 ####Running a linear regression
813
814 Reg <- lm(Prev_per_100 ~ MA, data = MA_V_Prev_per_100_Graphing.csv)
815
816 ##Review the results
817
818 Summary(Reg)
819
820
821 ####Supplemental table 1
822
823 ##Inport Data
824
825 setwd("/Users/Miles/Desktop")
826 GxDx <- read.csv("Updated_GxDx_SGA.csv")
827
828 ##Upload Packages
```

```
825
826 library(dplyr)
827 library(tidyverse)
828 library(pixiedust)
829 library(kableExtra)
830 library(webshot)
831
832 ##Make Table Backend
833
834 GxDx2 <- replace(GxDx, is.na(GxDx), "")
835
836 tbl3 <- dust(GxDx2)
837
838
839 ##Make the Table
840
841 tbl3 %>%
842   sprinkle_colnames(Genetic.Diagnosis = "Genetic Diagnosis", SGA = "SGA", AGA= "AGA", Crude.OR
843 = "Crude OR", X95_low = "Low 95 CI", X95_high = "High 95 CI") %>% kable() %>% kable_styling()
844 %>%
845   kable_classic(full_width = F, html_font = "Arial") %>%
846   row_spec(1,bold=T,hline_after = T) %>%
847   row_spec(9,bold=T,hline_after = T) %>%
848   row_spec(14,bold=T,hline_after = T) %>%
849   row_spec(21,bold=T,hline_after = T) %>%
850   add_indent(c(2,3,4,5,6,7,8,10,11,12,13,15,16,17,18,19,20,22,23,24))
851
852 ####Supplemental Figure 1
853
854 ## Load package
855 library(eulerr)
856
857 ## enter numbers of individuals in interaction of sets
858 fit1 <- euler(c("CDW"=0, "Fenton" = 0, "NICHD"=68986,
859   "CDW&Fenton"=0, "Fenton&NICHD"=3534, "CDW&NICHD"=2866,
860   "CDW&Fenton&NICHD"=33451))
861 ## plot Euler diagram
862 plot(fit1, quantities = TRUE, legend = TRUE)
863
864 ####Supplemental Figure 2
865 ##Same code as Figure 1 but added one line of code in data preparation
866
867 Prevalence4 <- Prevalence4 %>% filter(BirthNumber == "1")
868
869 ####Supplemental Figure 3
870 ##Same code as Figure 2 but added one line of code in data preparation
871 Outcome8 <- Outcome8 %>% filter(BirthNumber == "1")
872
873 ####Figure 1 Interaction Test
874 LogReg3 <- glm(SGA~ Race + MA + DY + Genetic + Any_Anom + Genetic*Any_Anom, data =
875 Prevalence4, family = "binomial")
876 anova(LogReg3, test='Chisq')
877 summary(LogReg3)
878
879 ####Figure 2 Interaction Test
```

```
880 LogReg5 <- glm(CritIllorDeath ~ Antenatal.Steroids + Sex + Race + GA + MVD0.2 + Any_Anom + DY +  
881 BW_Z_Score + Genetic + Deliv_Mode + Any_Anom + Genetic*Any_Anom, data = Outcome8,  
882 family = "binomial")  
883 anova(LogReg5, test='Chisq')  
884 summary(LogReg5)  
885  
886  
887
```